Novo Nordisk A/S (NYSE:NVO) finished Friday with an addition of $1.6 to close at $106.01, an upside of 1.53 percent. An average of 864,280 shares of common stock have been traded in the last five days. There was a gain of $3.67 in the past week, and it reached a new high 40 times over the past 12 months. The last 20 days have seen an average of 859,835 shares traded, while the 50-day average volume stands at 952,728.
NVO stock has increased by 3.83% in the last month. The company shares reached their 1-month lowest point of $94.83 on 09/28/21. With the stock rallying to its 52-week high on 08/20/21, shares of the company touched a low of $63.22 and a high of $107.24 in 52 weeks. It has reached a new high 39 times so far this year and achieved 51.77% or $36.16 in price. In spite of this, the price is down -1.15% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Novo Nordisk A/S (NVO) has a trailing price-to-earnings (P/E) ratio of 35.56, which compares with the 34.65 for the broader industry and 33.43 for the sector. In the last five years, Novo Nordisk A/S’s PE ratio has ranged between 34.70 and 14.36. The stock’s beta is 0.38. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.14, the price-to-book (PB) ratio at 23.88, and the price-to-cash flow ratio at 43.82.
Novo Nordisk A/S pays a $0.77 dividend per share annually. It offers a dividend yield of 0.73%. The company has a payout ratio of 298.60%. The company’s most recent quarterly dividend payment took place on Aug. 25, and it was $0.5571 a share, representing a down of -41.32% from $0.9494 last year. Its latest decrease dividend $0.3923 reported on Friday August 6 2021.Dividends have grown by 13.65% each year over the last three years.
The quick ratio of Novo Nordisk A/S for the three months ended June 29 was 0.80, and the current ratio was 1.10, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.19 and a total debt to equity ratio of 0.21 for the quarter ending June 29. Novo Nordisk A/S’s EBITDA margin for the year ending June 29 is 46.79%, while its operating margin for the same period stands at 41.40%. Its gross profit as reported stood at $16.24 billion compared to revenue of $19.45 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Novo Nordisk A/S’s return on assets was 30.40%. For the broader industry, ROE averaged -68.79 over the past year.
The analyst consensus anticipated Novo Nordisk A/S’s latest quarter earnings to come in at $0.76 per share, but it turned out to be $0.84, a 10.50% surprise. For the quarter, EBITDA amounted to $2.59 billion.
From a technical analysis perspective, let’s take a brief look at Novo Nordisk A/S (NVO) price momentum. RSI 9-day as of the close on 22 October was 77.90%, suggesting the stock is Overbought, with historical volatility in this time frame at 16.81%.
As of today, NVO’s price is $104.61 +3.59% or $3.67 from its 5-day moving average. NVO is currently trading +5.27% higher than its 20-day SMA and +34.45% higher than its 100-day SMA. However, the stock’s current price level is +4.17% above the SMA50 and +51.25% above the SMA200.
The stochastic %K and %D were 94.03% and 93.51%, respectively, and the average true range (ATR) was 1.62. With the 14-day stochastic at 99.23% and the average true range at 1.65, the RSI (14) stands at 69.67%. The stock has reached 2.32 on the 9-day MACD Oscillator while the 14-day reading was at 4.05.
Credit Suisse downgraded Novo Nordisk A/S (NYSE: NVO) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for Novo Nordisk A/S (NVO) among analysts is Hold. According to current brokerage recommendations, 5 brokerage firms advise that investors sell NVO, while 9 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 11 others rate it as a “buy”.
What is NVO’s price target for the next 12 months?
Analysts predict a range of price targets between $72.17 and $119.51, with a median target of $104.16. Taking a look at these predictions, the average price target given by analysts for Novo Nordisk A/S (NVO) stock is $100.45.